Gilead Buys $20.1 Million of Assembly Biosciences Stock
Gilead Sciences bought nearly 950,000 more shares of antiviral-therapeutics developer Assembly as part of an amended ...
Hosted on MSN26d
Gilead Stock Gains 15.4% in a Year: Should You Buy, Sell or Hold?
Gilead Sciences recently entered into a multi-target research collaboration with Terray Therapeutics to discover and develop novel small-molecule therapies for multiple targets. Gilead’s ...
Enid News & Eagle29d
Gilead and Terray Therapeutics Announce Multi-Target Research Collaboration to Discover and Develop Novel Small Molecule Therapies
Gilead Sciences, Inc. (Nasdaq: GILD) and Terray Therapeutics, Inc. announced today that the companies have entered into a strategic collaboration to discover and develop novel, small molecule ...
Business Wire2mon
Gilead’s Livdelzi (Seladelpar) Demonstrated a Sustained Efficacy and Long-Term Safety Profile in Management of Primary Biliary Cholangitis
Gilead Sciences. “With Livdelzi, we’ve introduced an effective and well tolerated option for people living with PBC, offering an important novel treatment option. We remain committed to ...
Business Wire29d
Gilead and Terray Therapeutics Announce Multi-Target Research Collaboration to Discover and Develop Novel Small Molecule Therapies
Gilead and Terray Will Leverage Terray’s tNova ... have entered into a strategic collaboration to discover and develop novel, small molecule therapies across multiple targets.
Nasdaq29d
Gilead and Terray Therapeutics Announce Multi-Target Research Collaboration to Discover and Develop Novel Small Molecule Therapies
-- Gilead and Terray Will Leverage Terray’s tNova Drug Discovery Platform to Identify Small Molecule Therapeutics Against Targets of Interest -- -- Gilead Has Exclusive Option to Develop and ...